Roberts Zachary 4
4 · Allogene Therapeutics, Inc. · Filed Jan 23, 2025
Insider Transaction Report
Form 4
Roberts Zachary
EVP of R&D
Transactions
- Sale
Common Stock
2025-01-21$1.78/sh−27,199$48,414→ 488,054 total
Footnotes (2)
- [F1]Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.78 to $1.805, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with in the rage set forth above.